Supplementary Methods

1. Definition of DLTs

• Clinically significant non-hematological toxicities (except for nausea, vomiting, and diarrhea) of grade 3 or higher
• Nausea, vomiting, and diarrhea of grade 3 or higher, uncontrollable by supportive therapy.
• Febrile neutropenia, or grade 4 neutropenia persisting for at least 5 days, even after receiving hematopoietic growth factor treatment.
• Grade 4 thrombocytopenia, or grade 3 thrombocytopenia with bleeding.
• Any toxicity that was at least possibly drug-related requiring the delay of study treatment longer than 8 days.

2. Pharmacokinetic analysis

The concentrations of OPB-111077 and its metabolites in plasma were analyzed using a validated liquid chromatography-tandem mass spectrometry method. The following parameters related to pharmacokinetics were assessed: maximum observed plasma concentration (C_{max}), minimum observed plasma concentration (C_{min}), time to C_{max} (t_{max}), apparent terminal elimination half-life (t_{1/2,z}), area under the concentration-time curve from hour 0 to the last measurable concentration (AUC_t), area under the concentration-time curve from hour 0 to hour 24 (AUC_{(0-24)}), area under the concentration-time curve within a dosing interval (AUC_{(0-tau)}), linearity index (LI), accumulation ratio for AUC_{(0-tau)} (R_{AUC(0-tau)}).